These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 26545947)

  • 1. [Role of rifaximin in the treatment of hepatic encephalopathy].
    Sanchez-Delgado J; Miquel M
    Gastroenterol Hepatol; 2016 Apr; 39(4):282-92. PubMed ID: 26545947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rifaximin in the treatment of hepatic encephalopathy].
    Lata J; Hůlek P; Fejfar T; Spicák J; Drastich P; Marecek Z; Brůha R; Husová L; Senkyrík M
    Vnitr Lek; 2002 Jun; 48(6):578-82. PubMed ID: 12132365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
    Bajaj JS
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hepatic encephalopathy in the hospital.
    Leise MD; Poterucha JJ; Kamath PS; Kim WR
    Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention of hepatic encephalopathy].
    Morillas RM; Sala M; Planas R
    Med Clin (Barc); 2014 Jun; 142(11):512-4. PubMed ID: 24480288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis.
    Bajaj JS; Barrett AC; Bortey E; Paterson C; Forbes WP
    Aliment Pharmacol Ther; 2015 Jan; 41(1):39-45. PubMed ID: 25339518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
    Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
    Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.
    Jiang Q; Jiang XH; Zheng MH; Jiang LM; Chen YP; Wang L
    Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1064-70. PubMed ID: 19047837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifaximin in the treatment of chronic hepatic encephalopathy.
    Puxeddu A; Quartini M; Massimetti A; Ferrieri A
    Curr Med Res Opin; 1995; 13(5):274-81. PubMed ID: 7555036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of rifaximin response in hepatic encephalopathy.
    Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
    J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.
    Sanyal A; Younossi ZM; Bass NM; Mullen KD; Poordad F; Brown RS; Vemuru RP; Mazen Jamal M; Huang S; Merchant K; Bortey E; Forbes WP
    Aliment Pharmacol Ther; 2011 Oct; 34(8):853-61. PubMed ID: 21848797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
    Kang SH; Lee YB; Lee JH; Nam JY; Chang Y; Cho H; Yoo JJ; Cho YY; Cho EJ; Yu SJ; Kim MY; Kim YJ; Baik SK; Yoon JH
    Aliment Pharmacol Ther; 2017 Nov; 46(9):845-855. PubMed ID: 28836723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifaximin: new therapeutic indication and future directions.
    Rivkin A; Gim S
    Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.
    Mas A; Rodés J; Sunyer L; Rodrigo L; Planas R; Vargas V; Castells L; Rodríguez-Martínez D; Fernández-Rodríguez C; Coll I; Pardo A;
    J Hepatol; 2003 Jan; 38(1):51-8. PubMed ID: 12480560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifaximin for the treatment of hepatic encephalopathy.
    Mullen K; Prakash R
    Expert Rev Gastroenterol Hepatol; 2010 Dec; 4(6):665-77. PubMed ID: 21108586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease.
    Khokhar N; Qureshi MO; Ahmad S; Ahmad A; Khan HH; Shafqat F; Salih M
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1420-2. PubMed ID: 25867912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.